summit therapeutics limited
summit therapeutics limited Company Information
Company Number
05197494
Website
www.summitplc.comRegistered Address
136a eastern avenue, milton park, abingdon, oxfordshire, OX14 4SB
Industry
Research and experimental development on biotechnology
Telephone
01235443939
Next Accounts Due
33 days late
Group Structure
View All
Shareholders
summit therapeutics inc. 100%
summit therapeutics limited Estimated Valuation
Pomanda estimates the enterprise value of SUMMIT THERAPEUTICS LIMITED at £0 based on a Turnover of £0 and 1.34x industry multiple (adjusted for size and gross margin).
summit therapeutics limited Estimated Valuation
Pomanda estimates the enterprise value of SUMMIT THERAPEUTICS LIMITED at £0 based on an EBITDA of £-217.8m and a 5.36x industry multiple (adjusted for size and gross margin).
summit therapeutics limited Estimated Valuation
Pomanda estimates the enterprise value of SUMMIT THERAPEUTICS LIMITED at £622.9m based on Net Assets of £272.5m and 2.29x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Summit Therapeutics Limited Overview
Summit Therapeutics Limited is a live company located in abingdon, OX14 4SB with a Companies House number of 05197494. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in August 2004, it's largest shareholder is summit therapeutics inc. with a 100% stake. Summit Therapeutics Limited is a mature, unknown sized company, Pomanda has estimated its turnover at £0 with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Summit Therapeutics Limited Health Check
Pomanda's financial health check has awarded Summit Therapeutics Limited a 2 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 2 areas for improvement. Company Health Check FAQs
2 Strong
0 Regular
2 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Summit Therapeutics Limited
- - Industry AVG
Growth
3 year (CAGR) sales growth of -100%, show it is growing at a slower rate (13.8%)
- - Summit Therapeutics Limited
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- - Summit Therapeutics Limited
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- - Summit Therapeutics Limited
- - Industry AVG
Employees
with 1 employees, this is below the industry average (42)
- Summit Therapeutics Limited
- - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- Summit Therapeutics Limited
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- Summit Therapeutics Limited
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Summit Therapeutics Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Summit Therapeutics Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Summit Therapeutics Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 13690 weeks, this is more cash available to meet short term requirements (32 weeks)
- - Summit Therapeutics Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 0%, this is a lower level of debt than the average (51.9%)
- - Summit Therapeutics Limited
- - Industry AVG
SUMMIT THERAPEUTICS LIMITED financials
Summit Therapeutics Limited's latest turnover from December 2022 is 0 and the company has net assets of £272.5 million. According to their latest financial statements, we estimate that Summit Therapeutics Limited has 1 employee and maintains cash reserves of £717.4 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Jan 2019 | Jan 2018 | Jan 2017 | Jan 2016 | Jan 2015 | Jan 2014 | Jan 2013 | Jan 2012 | Jan 2011 | Jan 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 0 | 0 | 0 | 583,000 | 43,012,000 | 12,360,000 | 2,304,000 | 0 | 2,148,000 | 1,844,000 | 1,814,000 | 1,765,000 | 763,000 | 189,000 |
| Other Income Or Grants | 0 | 0 | 0 | 0 | ||||||||||
| Cost Of Sales | 0 | 0 | 0 | 0 | ||||||||||
| Gross Profit | 1,814,000 | 1,765,000 | 763,000 | 189,000 | ||||||||||
| Admin Expenses | 6,391,000 | 4,767,000 | 6,692,000 | 5,949,000 | ||||||||||
| Operating Profit | -217,795,067 | -14,938,452 | 49,898,294 | -25,332,000 | 2,673,000 | -25,884,000 | -24,853,000 | -20,346,000 | -12,711,000 | 6,709,000 | -4,577,000 | -3,002,000 | -5,929,000 | -5,760,000 |
| Interest Payable | 0 | 0 | 0 | 228,000 | 467,000 | 1,164,000 | 862,000 | 2,879,000 | 0 | 0 | 0 | 3,000 | 4,000 | 67,000 |
| Interest Receivable | 0 | 0 | 0 | 4,000 | 2,788,000 | 3,096,000 | 8,000 | 30,000 | 51,000 | 9,000 | 11,000 | 7,000 | 17,000 | 8,000 |
| Pre-Tax Profit | -217,795,067 | -14,938,452 | 49,898,294 | -25,556,000 | 4,994,000 | -23,952,000 | -25,707,000 | -23,195,000 | -12,660,000 | -6,700,000 | -4,566,000 | -2,998,000 | -5,916,000 | -5,819,000 |
| Tax | 0 | 0 | 0 | 3,524,000 | 2,496,000 | 3,762,000 | 4,336,000 | 3,058,000 | 1,297,000 | 607,000 | 341,000 | 304,000 | 1,226,000 | -372,000 |
| Profit After Tax | -217,795,067 | -14,938,452 | 49,898,294 | -22,032,000 | 7,490,000 | -20,190,000 | -21,371,000 | -20,137,000 | -11,363,000 | -6,093,000 | -4,225,000 | -2,694,000 | -4,690,000 | -6,191,000 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Profit | -217,795,067 | -14,938,452 | 49,898,294 | -22,032,000 | 7,490,000 | -20,190,000 | -21,371,000 | -20,137,000 | -11,363,000 | -6,093,000 | -4,225,000 | -2,694,000 | -4,690,000 | -6,191,000 |
| Employee Costs | 0 | 0 | 0 | 8,104,000 | 14,245,000 | 10,093,000 | 8,077,000 | 5,373,000 | 4,033,000 | 1,640,000 | 1,878,000 | 1,713,000 | 1,950,000 | 3,028,000 |
| Number Of Employees | 65 | 74 | 60 | 44 | 37 | 23 | 17 | 27 | 31 | 31 | 73 | |||
| EBITDA* | -217,795,067 | -14,938,452 | 49,898,294 | -24,300,000 | 3,799,000 | -25,638,000 | -24,795,000 | -20,298,000 | -12,678,000 | 6,735,000 | -3,585,000 | -2,814,000 | -5,764,000 | -5,076,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Jan 2019 | Jan 2018 | Jan 2017 | Jan 2016 | Jan 2015 | Jan 2014 | Jan 2013 | Jan 2012 | Jan 2011 | Jan 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 | 1,167,000 | 1,540,000 | 809,000 | 116,000 | 83,000 | 55,000 | 43,000 | 23,000 | 149,000 | 260,000 | 335,000 |
| Intangible Assets | 0 | 0 | 0 | 11,764,000 | 12,418,000 | 17,263,000 | 4,134,000 | 4,137,000 | 4,147,000 | 4,157,000 | 171,000 | 1,104,000 | 1,100,000 | 4,535,000 |
| Investments & Other | 271,243,113 | 162,547,991 | 161,439,760 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 271,243,113 | 162,547,991 | 161,439,760 | 12,931,000 | 13,958,000 | 18,072,000 | 4,250,000 | 4,220,000 | 4,202,000 | 4,200,000 | 194,000 | 1,253,000 | 1,360,000 | 4,870,000 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 | 566,000 | 2,267,000 | 0 | 0 | 0 | 0 | 0 | 51,000 | 47,000 | 32,000 | 41,000 |
| Group Debtors | 527,820 | 30,711,297 | 1,517,918 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 3,648 | 21,619 | 399,790 | 7,550,000 | 11,224,000 | 11,134,000 | 5,275,000 | 4,533,000 | 2,630,000 | 431,000 | 410,000 | 246,000 | 449,000 | 205,000 |
| Cash | 717,358 | 1,059,951 | 39,914,636 | 48,417,000 | 26,858,000 | 20,102,000 | 28,062,000 | 16,304,000 | 11,265,000 | 2,030,000 | 3,379,000 | 2,076,000 | 3,250,000 | 6,082,000 |
| misc current assets | 0 | 0 | 0 | 3,659,000 | 6,328,000 | 4,654,000 | 0 | 0 | 1,299,000 | 634,000 | 343,000 | 274,000 | 0 | 306,000 |
| total current assets | 1,248,826 | 31,792,867 | 41,832,344 | 60,192,000 | 46,677,000 | 35,890,000 | 33,337,000 | 20,837,000 | 15,194,000 | 3,095,000 | 4,183,000 | 2,643,000 | 3,731,000 | 6,634,000 |
| total assets | 272,491,939 | 194,340,858 | 203,272,104 | 73,123,000 | 60,635,000 | 53,962,000 | 37,587,000 | 25,057,000 | 19,396,000 | 7,295,000 | 4,377,000 | 3,896,000 | 5,091,000 | 11,504,000 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 0 | 0 | 0 | 3,389,000 | 4,422,000 | 4,414,000 | 906,000 | 716,000 | 1,195,000 | 349,000 | 254,000 | 372,000 | 332,000 | 149,000 |
| Group/Directors Accounts | 0 | 42,198,345 | 36,863,846 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 358,000 | 358,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 2,724 | 39,530 | 511,075 | 5,847,000 | 8,314,000 | 18,352,000 | 9,990,000 | 2,490,000 | 2,526,000 | 1,520,000 | 1,272,000 | 913,000 | 876,000 | 955,000 |
| total current liabilities | 2,725 | 42,237,875 | 37,374,921 | 9,594,000 | 13,094,000 | 22,766,000 | 10,896,000 | 3,206,000 | 3,721,000 | 1,869,000 | 1,526,000 | 1,285,000 | 1,208,000 | 1,104,000 |
| loans | 0 | 0 | 0 | 640,000 | 1,294,000 | 3,090,000 | 5,919,000 | 5,034,000 | 0 | 0 | 0 | 0 | 0 | 2,360,000 |
| hp & lease commitments | 0 | 0 | 0 | 320,000 | 647,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 374,000 | 831,000 | 27,270,000 | 23,615,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 7,220,000 | 7,052,000 | 8,040,000 | 1,300,000 | 1,474,000 | 1,418,000 | 1,328,000 | 0 | 410,000 | 410,000 | 1,884,000 |
| total long term liabilities | 0 | 0 | 0 | 4,304,000 | 5,004,000 | 34,380,000 | 30,184,000 | 5,771,000 | 709,000 | 664,000 | 0 | 205,000 | 205,000 | 2,122,000 |
| total liabilities | 2,725 | 42,237,875 | 37,374,921 | 13,898,000 | 18,098,000 | 57,146,000 | 41,080,000 | 8,977,000 | 4,430,000 | 2,533,000 | 1,526,000 | 1,490,000 | 1,413,000 | 3,226,000 |
| net assets | 272,489,215 | 152,102,983 | 165,897,183 | 59,225,000 | 42,537,000 | -3,184,000 | -3,493,000 | 16,080,000 | 14,966,000 | 4,762,000 | 2,851,000 | 2,406,000 | 3,678,000 | 8,278,000 |
| total shareholders funds | 272,489,215 | 152,102,983 | 165,897,183 | 59,225,000 | 42,537,000 | -3,184,000 | -3,493,000 | 16,080,000 | 14,966,000 | 4,762,000 | 2,851,000 | 2,406,000 | 3,678,000 | 8,278,000 |
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Jan 2019 | Jan 2018 | Jan 2017 | Jan 2016 | Jan 2015 | Jan 2014 | Jan 2013 | Jan 2012 | Jan 2011 | Jan 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | -217,795,067 | -14,938,452 | 49,898,294 | -25,332,000 | 2,673,000 | -25,884,000 | -24,853,000 | -20,346,000 | -12,711,000 | 6,709,000 | -4,577,000 | -3,002,000 | -5,929,000 | -5,760,000 |
| Depreciation | 0 | 0 | 0 | 272,000 | 297,000 | 140,000 | 48,000 | 38,000 | 23,000 | 17,000 | 48,000 | 95,000 | 165,000 | 684,000 |
| Amortisation | 0 | 0 | 0 | 760,000 | 829,000 | 106,000 | 10,000 | 10,000 | 10,000 | 9,000 | 944,000 | 93,000 | 0 | 0 |
| Tax | 0 | 0 | 0 | 3,524,000 | 2,496,000 | 3,762,000 | 4,336,000 | 3,058,000 | 1,297,000 | 607,000 | 341,000 | 304,000 | 1,226,000 | -372,000 |
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | -30,201,448 | 28,815,208 | -6,198,292 | -3,018,000 | 2,357,000 | 5,859,000 | 742,000 | 1,903,000 | 2,199,000 | -30,000 | 168,000 | -188,000 | 235,000 | 246,000 |
| Creditors | 0 | 0 | -3,389,000 | -1,025,000 | 8,000 | 3,508,000 | 190,000 | -479,000 | 846,000 | 95,000 | -118,000 | 40,000 | 183,000 | 149,000 |
| Accruals and Deferred Income | -36,806 | -471,545 | -5,709,925 | -39,401,000 | -36,477,000 | 12,017,000 | 31,115,000 | -36,000 | 1,006,000 | 248,000 | 359,000 | 37,000 | -79,000 | 955,000 |
| Deferred Taxes & Provisions | 0 | 0 | -7,220,000 | -820,000 | -988,000 | 6,740,000 | -174,000 | 56,000 | 90,000 | 1,328,000 | -410,000 | 0 | -1,474,000 | 1,884,000 |
| Cash flow from operations | -187,630,425 | -44,225,205 | 39,777,661 | -59,004,000 | -33,519,000 | -5,470,000 | 9,930,000 | -19,602,000 | -11,638,000 | 9,043,000 | -3,581,000 | -2,245,000 | -6,143,000 | -2,706,000 |
| Investing Activities | ||||||||||||||
| capital expenditure | ||||||||||||||
| Change in Investments | 108,695,122 | 1,108,231 | 161,439,760 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | -42,198,345 | 5,334,499 | 36,863,846 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | -640,000 | -2,450,000 | -1,796,000 | -2,829,000 | 885,000 | 5,034,000 | 0 | 0 | 0 | 0 | -2,360,000 | 2,360,000 |
| Hire Purchase and Lease Commitments | 0 | 0 | -678,000 | 678,000 | 1,005,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||||||||
| interest | 0 | 0 | 0 | -224,000 | 2,321,000 | 1,932,000 | -854,000 | -2,849,000 | 51,000 | 9,000 | 11,000 | 4,000 | 13,000 | -59,000 |
| cash flow from financing | 295,982,954 | 6,478,751 | 92,319,735 | 82,445,000 | 39,761,000 | 19,602,000 | 1,829,000 | 23,436,000 | 21,618,000 | 8,013,000 | 4,681,000 | 1,426,000 | -2,257,000 | 16,770,000 |
| cash and cash equivalents | ||||||||||||||
| cash | -342,593 | -38,854,685 | -8,502,364 | 28,315,000 | 6,756,000 | -7,960,000 | 11,758,000 | 5,039,000 | 9,235,000 | -1,349,000 | 1,303,000 | -1,174,000 | -2,832,000 | 6,082,000 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | -342,593 | -38,854,685 | -8,502,364 | 28,315,000 | 6,756,000 | -7,960,000 | 11,758,000 | 5,039,000 | 9,235,000 | -1,349,000 | 1,303,000 | -1,174,000 | -2,832,000 | 6,082,000 |
summit therapeutics limited Credit Report and Business Information
Summit Therapeutics Limited Competitor Analysis
Perform a competitor analysis for summit therapeutics limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other mature companies, companies in OX14 area or any other competitors across 12 key performance metrics.
summit therapeutics limited Ownership
SUMMIT THERAPEUTICS LIMITED group structure
Summit Therapeutics Limited has 9 subsidiary companies.
Ultimate parent company
SUMMIT THERAPEUTICS INC.
#0135312
1 parent
SUMMIT THERAPEUTICS LIMITED
05197494
9 subsidiaries
summit therapeutics limited directors
Summit Therapeutics Limited currently has 4 directors. The longest serving directors include Mr Robert Duggan (Dec 2019) and Dr David Powell (Jan 2021).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Robert Duggan | England | 80 years | Dec 2019 | - | Director |
| Dr David Powell | England | 56 years | Jan 2021 | - | Director |
| Ms Manmeet Soni | England | 47 years | Dec 2023 | - | Director |
| Mr Bhaskar Anand | United Kingdom | 47 years | Apr 2024 | - | Director |
P&L
December 2022turnover
0
0%
operating profit
-217.8m
+1358%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2022net assets
272.5m
+0.79%
total assets
272.5m
+0.4%
cash
717.4k
-0.32%
net assets
Total assets minus all liabilities
summit therapeutics limited company details
company number
05197494
Type
Private limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
August 2004
age
20
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
December 2022
previous names
summit therapeutics plc (September 2020)
summit corporation plc (February 2015)
See moreaccountant
-
auditor
PRICEWATERHOUSECOOPERS LLP
address
136a eastern avenue, milton park, abingdon, oxfordshire, OX14 4SB
Bank
HSBC BANK PLC
Legal Advisor
-
summit therapeutics limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to summit therapeutics limited.
summit therapeutics limited Companies House Filings - See Documents
| date | description | view/download |
|---|
